Disease · MONDO_0044903
Comparisons in its trials38
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 38
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm): Key Secondary: Number of Participants With TSS50 Response at Week 24 | 112 of 214 | 100 of 216 | 430 | NCT04603495 | Trial comparisons |
| Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm): Number of Participants With Splenic Response by Central Radiology Reads at Week 24 | 141 of 214 | 76 of 216 | 430 | NCT04603495 | Trial comparisons |
| Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm): Number of Participants With Modified Total Symptom Score (mTSS) Response at Week 24 | 120 of 214 | 104 of 216 | 430 | NCT04603495 | Trial comparisons |
| Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm): Number of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence | 0 of 214 | 0 of 216 | 430 | NCT04603495 | Trial comparisons |
| Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm): deaths from any cause | 11 of 212 | 10 of 214 | 426 | NCT04603495 | Trial comparisons |
| Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm): serious adverse events | 63 of 212 | 63 of 214 | 426 | NCT04603495 | Trial comparisons |
| Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm): Number of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 24 | 36 of 192 | 21 of 188 | 380 | NCT04603495 | Trial comparisons |
| Pacritinib vs Best Available Therapy: Spleen Volume Reduction | 42 of 220 | 5 of 107 | 327 | NCT01773187 | Trial comparisons |
| Pacritinib vs Best Available Therapy: deaths from any cause | 27 of 220 | 3 of 106 | 326 | NCT01773187 | Trial comparisons |
| Pacritinib vs Best Available Therapy: serious adverse events | 117 of 220 | 33 of 106 | 326 | NCT01773187 | Trial comparisons |
| Parsaclisib Plus Ruxolitinib vs Placebo Plus Ruxolitinib: Number of Participants With Any Grade 3 or Higher TEAE | 75 of 125 | 75 of 127 | 252 | NCT04551066 | Trial comparisons |
| Parsaclisib Plus Ruxolitinib vs Placebo Plus Ruxolitinib: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 117 of 125 | 119 of 127 | 252 | NCT04551066 | Trial comparisons |
| Parsaclisib Plus Ruxolitinib vs Placebo Plus Ruxolitinib: deaths from any cause | 6 of 125 | 3 of 127 | 252 | NCT04551066 | Trial comparisons |
| Parsaclisib Plus Ruxolitinib vs Placebo Plus Ruxolitinib: serious adverse events | 26 of 125 | 18 of 127 | 252 | NCT04551066 | Trial comparisons |
| Pacritinib vs Best Available Therapy: Total Symptom Score (TSS) Reduction | 19 of 100 | 5 of 48 | 148 | NCT01773187 | Trial comparisons |
| Imetelstat 4.7 mg/kg vs Imetelstat 9.4 mg/kg: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 47 of 48 | 59 of 59 | 107 | NCT02426086 | Trial comparisons |
| MMB 200 mg QD + Placebo vs DAN 300 mg BID + Placebo: Number of Baseline TD Participants With TI Status at Week 24 | 9 of 63 | 3 of 34 | 97 | NCT04173494 | Trial comparisons |
| Ruxolitinib - Weeks 1-16 vs Ruxolitinib - After Week 16: serious adverse events | 6 of 41 | 9 of 41 | 82 | NCT01340651 | Trial comparisons |
| Sibling Donor vs Unrelated Donor: The Primary Endpoint is Progression-free Survival. | 24 of 32 | 11 of 34 | 66 | NCT00572897 | Trial comparisons |
| Sibling Donor vs Unrelated Donor: Overall Survival | 25 of 32 | 11 of 34 | 66 | NCT00572897 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044903/comparisons